Cover Image
市場調查報告書

EpiCast Report:癲癇的流行病學的預測

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 579812
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:癲癇的流行病學的預測 EpiCast Report: Epilepsy - Epidemiology Forecast to 2026
出版日期: 2017年10月12日 內容資訊: 英文 45 Pages
簡介

本報告提供全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的癲癇發病情形和今後預測相關分析,疾病的調查特徵(風險要素和主要的共生病症等)全球各國的趨勢,目前患病者的發病情形,今後10年的患病數量的預測值等。

第1章 目錄

第2章 癲癇:摘要整理

  • 相關分析
  • 出版預定的相關分析

第3章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全球各國的過去趨勢
    • 美國
    • (5EU)歐洲主要5個國家
    • 日本
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 癲癇的流行病學的預測 (今後11年份)
    • 有癲癇發病經歷的人數
    • 癲癇的現在治療中的患病者
    • 癲癇的現在治療中的患病者:各年齡層
    • 癲癇的現在治療中的患病者:男女
    • 癲癇的現在治療中的患病者:發作的各類型
    • 癲癇的現在治療中的患病者(有藥物抗性)
  • 議論
    • 流行病學的預測
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER163-17

Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014).

In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the lifetime diagnosed prevalent cases of epilepsy will increase from around 4.5 million cases in 2016 to about 4.7 million cases in 2026, at an AGR of close to 0.6%.

In 2016, there were about 5.6 million active diagnosed prevalent cases of epilepsy in the 7MM, which is expected to increase to just over 6 million cases by 2026, at an AGR of around 0.6%. Among the 7MM, the US had the highest number of active diagnosed prevalent cases of epilepsy in 2016 and 2026, at around 3.2 million cases and about 3.5 million cases, respectively. However, France will have the highest growth in the 7MM, at an AGR of over 4%.

The report "EpiCast Report: Epilepsy - Epidemiology Forecast to 2026", provides an overview of the risk factors and the global and historical trends for epilepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026.

Scope

  • The Epilepsy EpiCast Report provides an overview of the risk factors and global trends of epilepsy in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026. The lifetime and active diagnosed prevalent cases are segmented by sex and age (ranging from age 0 to ages 80 years and older). The active diagnosed prevalent cases are further segmented by seizure type (generalized, focal, unclassified/unknown) and drug resistance.
  • The epilepsy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Epilepsy EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
  • Quantify patient populations in the global epilepsy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for epilepsy therapeutics in each of the markets covered.
  • Understand seizure type and drug resistance in active diagnosed prevalent cases of epilepsy.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Epilepsy: Executive Summary 4

  • 2.1 Related Reports 7
  • 2.2 Upcoming Related Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
    • 3.3.1 US 11
    • 3.3.2 5EU 12
    • 3.3.3 Japan 12
  • 3.4 Forecast Methodology 13
    • 3.4.1 Sources 14
    • 3.4.2 Forecast Assumptions and Methods 18
  • 3.5 Epidemiological Forecast for Epilepsy (2016-2026) 28
    • 3.5.1 Lifetime Diagnosed Prevalent Cases of Epilepsy 28
    • 3.5.2 Active Diagnosed Prevalent Cases of Epilepsy 29
    • 3.5.3 Age-Specific Active Diagnosed Prevalent Cases of Epilepsy 30
    • 3.5.4 Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy 31
    • 3.5.5 Active Diagnosed Prevalent Cases by Seizure Type 32
    • 3.5.6 Drug Resistant Active Diagnosed Prevalent Cases 33
  • 3.6 Discussion 34
    • 3.6.1 Epidemiological Forecast Insight 34
    • 3.6.2 Limitations of the Analysis 36
    • 3.6.3 Strengths of the Analysis 36

4 Appendix 37

  • 4.1 Bibliography 37
  • 4.2 Primary Research - Prescriber Survey 42
  • 4.3 About the Authors 42
    • 4.3.1 Epidemiologist 42
    • 4.3.2 Reviewers 42
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology 43
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy 44
  • 4.4 About GlobalData 45
  • 4.5 Contact Us 45
  • 4.6 Disclaimer 45

List of Tables

  • Table 1: Risk Factors and Comorbidities for Epilepsy 9
  • Table 2: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026. 29
  • Table 3: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026 30
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 42

List of Figures

  • Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 5
  • Figure 2: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 3: 7MM Age-Standardized Lifetime Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 10
  • Figure 4: 7MM Age-standardized Active Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 11
  • Figure 5: The Sources Used to Calculate the Lifetime Diagnosed Prevalence of Epilepsy 14
  • Figure 6: The Sources Used and Not Used in the Forecast for the Active Diagnosed Prevalence 15
  • Figure 7: The Sources Used and Not Used in the Forecast for the Seizure Type Distribution of Active Diagnosed Prevalent Cases 17
  • Figure 8: The Sources Used in the Forecast for the Drug Resistant Active Diagnosed Prevalent Cases 18
  • Figure 9: 7MM, Age-Specific Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, 2016 31
  • Figure 10: 7MM Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy, All Ages, 2016. 32
  • Figure 11: 7MM, Active Diagnosed Prevalent Cases of Epilepsy by Seizure Type, Men and Women, All Ages, 2016 33
  • Figure 12: 7MM, Active Diagnosed Prevalent Cases by Response to AED Treatment, Men and Women, All Ages, 2016. 34
Back to Top